Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Peptide Science

• Publication date

  2015-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/psc.2727PMID 25521062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of a neuromedin U–human serum albumin conjugate as a long‐acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide

  2014cited by this paper
• The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

  2014cited by this paper
• The future role of gut hormones in the treatment of obesity

  2014cited by this paper
• Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides

  2013cited by this paper
• Using albumin to improve the therapeutic properties of diabetes treatments

  2012cited by this paper
• Obesity and Appetite Control

  2012cited by this paper
• PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes.

  2012cited by this paper
• Effects of peripherally administered neuromedin U on energy and glucose homeostasis.

  2011cited by this paper
• Long-acting lipidated analogue of human pancreatic polypeptide is slowly released into circulation.

  2011cited by this paper
• Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides.

  2011cited by this paper
• Postprandial Insulin Secretion After Gastric Bypass Surgery

  2011cited by this paper
• An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future

  2011cited by this paper
• Modulation of the constitutive activity of the ghrelin receptor by use of pharmacological tools and mutagenesis.

  2010cited by this paper
• Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat

  2010cited by this paper
• Prevalence and trends in obesity among US adults, 1999-2008.

  2010cited by this paper
• Potential of liraglutide in the treatment of patients with type 2 diabetes

  2009cited by this paper
• The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).

  2009cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• Bariatric Surgery: The Past, Present, and Future

  2008cited by this paper
• Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness.

  2007cited by this paper
• Expression of neuromedins S and U and their receptors in the hypothalamus and endocrine glands of the rat.

  2007cited by this paper
• Association between neuromedin U gene variants and overweight and obesity.

  2006cited by this paper
• Neuromedin U in the Paraventricular and Arcuate Hypothalamic Nuclei Increases Non‐Exercise Activity Thermogenesis

  2006cited by this paper
• Protein drug stability: a formulation challenge

  2005cited by this paper
• Neuromedin U and Its Receptors: Structure, Function, and Physiological Roles

  2004cited by this paper
• Effect of pegylation on pharmaceuticals

  2003cited by this paper
• Neuromedin U and Neuromedin U receptor‐2 expression in the mouse and rat hypothalamus: effects of nutritional status

  2003cited by this paper
• Cloning and characterization of murine neuromedin U receptors.

  2002cited by this paper
• Identification and Characterization of Two Neuromedin U Receptors Differentially Expressed in Peripheral Tissues and the Central Nervous System*

  2000cited by this paper
• Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.

  2000cited by this paper
• Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U.

  2000cited by this paper
• Neuromedin U Is a Potent Agonist at the Orphan G Protein-coupled Receptor FM3*

  2000cited by this paper
• Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3).

  2000cited by this paper
• Central effects of neuromedin U in the regulation of energy homeostasis.

  2000cited by this paper
• Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity.

  2000cited by this paper
• Identification and Functional Characterization of a Novel Subtype of Neuromedin U Receptor*

  2000cited by this paper
• Identification of receptors for neuromedin U and its role in feeding

  2000cited by this paper
• Identification of Neuromedin U as the Cognate Ligand of the Orphan G Protein-coupled Receptor FM-3*

  2000cited by this paper
• Structure-activity relationships of neuromedin U. I. Contractile activity of dog neuromedin U-related peptides on isolated chicken crop smooth muscle.

  1995cited by this paper
• Contractile activity of porcine neuromedin U-25 and various neuromedin U-related peptide fragments on isolated chicken crop smooth muscle.

  1992cited by this paper
• Structure-activity relationships of rat neuromedin U for smooth muscle contraction.

  1991cited by this paper
• Occurrence and developmental pattern of neuromedin U-immunoreactive nerves in the gastrointestinal tract and brain of the rat.

  1988cited by this paper
• Neuromedin U--a study of its distribution in the rat.

  1987cited by this paper
• Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord.

  1985cited by this paper

• Engineered Neuromedin U Promotes Type 2 Innate Immunity and Renoprotection in Acute Kidney Injury.

  2025cites this paper
• Brain targeting for the treatment of obesity: update of current knowledge and potential applications of nanomedicine and peptide conjugation

  2025influential citation
• Suppressive Effects of Neuromedin U Receptor 2-Selective Peptide Agonists on Appetite and Prolactin Secretion in Mice.

  2024cites this paper
• The association of Neuromedin U levels and non-alcoholic fatty liver disease: A comparative analysis

  2024cites this paper
• The Neuromedin U system: pharmacological implications for the treatment of obesity and binge eating behavior.

  2023cites this paper
• Derivatization with fatty acids in peptide and protein drug discovery

  2022cites this paper
• Regulation of feeding and therapeutic application of bioactive peptides.

  2022cites this paper
• Peptide Tool-Driven Functional Elucidation of Biomolecules Related to Endocrine System and Metabolism.

  2022cites this paper
• Purification of Modified Therapeutic Proteins Available on the Market: An Analysis of Chromatography-Based Strategies

  2021cites this paper
• A chemically stable peptide agonist to neuromedin U receptor type 2.

  2020cites this paper
• Therapeutic peptide delivery via aptamer-displaying, disulfide-linked peptide amphiphile micelles

  2020cites this paper
• Evaluation of VGF peptides as potential anti-obesity candidates in pre-clinical animal models.

  2020cites this paper
• Animal Models of Type 2 Diabetes, Obesity and Nonalcoholic Steatohepatitis – Clinical Translatability and Applicability in Preclinical Drug Development

  2019cites this paper
• Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice

  2018influential citation
• Synthesis and in Vitro Evaluation of Stabilized and Selective Neuromedin U-1 Receptor Agonists.

  2018cites this paper
• Antimicrobial activity of linear lipopeptides derived from BP100 towards plant pathogens

  2018cites this paper
• Development of potent and proteolytically stable human neuromedin U receptor agonists.

  2018cites this paper
• Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.

  2017cites this paper
• Neoglycolipids for Prolonging the Effects of Peptides: Self-Assembling Glucagon-like Peptide 1 Analogues with Albumin Binding Properties and Potent in Vivo Efficacy.

  2017cites this paper
• A novel LRP1-binding peptide L57 that crosses the blood brain barrier

  2017cites this paper
• A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects.

  2017cites this paper
• A potent neuromedin U receptor 2-selective alkylated peptide.

  2017cites this paper
• Discovery of a Human Neuromedin U Receptor 1-Selective Hexapeptide Agonist with Enhanced Serum Stability.

  2017cites this paper
• Micellar Nanomedicine of Novel Fatty Acid Modified Xenopus Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes.

  2017cites this paper
• Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation

  2016cites this paper
• Acylation of Therapeutic Peptides: Interaction with Lipid Membranes and its Implications in Oral Delivery

  2016cites this paper
• Identification of a degrading enzyme in human serum that hydrolyzes a C‐terminal core sequence of neuromedin U

  2016cites this paper
• Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide

  2016cites this paper
• Acylation of salmon calcitonin modulates in vitro intestinal peptide flux through membrane permeability enhancement.

  2015cites this paper
• Neuromedin U inhibits food intake partly by inhibiting gastric emptying.

  2015cites this paper